Compare AbbVie Inc (ABBV) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VanEck Vietnam ETF — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while VanEck Vietnam ETF trades at $18.27. The key difference: AbbVie Inc pays a 2.72% dividend while VanEck Vietnam ETF pays none, and AbbVie Inc is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | VNM | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Sector/Thematic |
52-Week High | $261.07 | $19.80 |
52-Week Low | $184.85 | $14.51 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
VNM trades at $18.19, down 1.62% on the day, with technical indicators signaling a bearish trend. The stock faces selling pressure from moving averages and oscillators, while support and resistance cluster around $18. Recent news highlights underperformance relative to emerging markets and global equities, compounded by Vietnam-specific risks like power grid strain from heatwaves.
The outlook remains cautious due to weak technical momentum and external headwinds. Investment opportunities hinge on Vietnam's economic resilience and potential foreign inflows from FTSE Russell's reclassification. Key risks include geopolitical tensions, climate impacts on infrastructure, and sustained underperformance versus peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
